About ADMA Biologics
ADMA Biologics is a company based in Ramsey (United States) founded in 2005 by Adam Grossman. ADMA Biologics has raised $17.55 million across 6 funding rounds from investors including Hercules Capital, Oxford Finance and Perceptive Advisors. The company has 685 employees as of December 31, 2024. ADMA Biologics offers products and services including ASCENIV, BIVIGAM, and Nabi-HB. ADMA Biologics operates in a competitive market with competitors including Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.
- Headquarter Ramsey, United States
- Employees 685 as on 31 Dec, 2024
- Founders Adam Grossman
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Adma Biologics Inc
-
Annual Revenue
$426.45 M (USD)65.15as on Dec 31, 2024
-
Net Profit
$197.67 M (USD)0as on Dec 31, 2024
-
EBITDA
$147.03 M (USD)390.68as on Dec 31, 2024
-
Total Equity Funding
$17.55 M (USD)
in 6 rounds
-
Latest Funding Round
$72.5 M (USD), Debt – Conventional
Feb 12, 2019
-
Investors
Hercules Capital
& 4 more
-
Employee Count
685
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of ADMA Biologics
ADMA Biologics is a publicly listed company on the NASDAQ with ticker symbol ADMA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of ADMA Biologics
ADMA Biologics offers a comprehensive portfolio of products and services, including ASCENIV, BIVIGAM, and Nabi-HB.
Treatment for primary immunodeficiency diseases.
Immune globulin product for medical applications.
Hepatitis B immune globulin for infection prevention.
People of ADMA Biologics
Unlock access to complete
Unlock access to complete
Funding Insights of ADMA Biologics
ADMA Biologics has successfully raised a total of $17.55M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $72.5 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ADMA Biologics
ADMA Biologics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Hercules Capital, Oxford Finance and Perceptive Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Venture debt firm focused on the life sciences sector
|
Locked | Locked | Locked | |
|
Venture debt financing is provided to companies in multiple sectors.
|
Locked | Locked | Locked |
Investor details for ADMA Biologics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ADMA Biologics
Investment portfolio details for ADMA Biologics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ADMA Biologics
Detailed financials for ADMA Biologics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Adma Biologics Comparisons
Peer comparison for ADMA Biologics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ADMA Biologics
ADMA Biologics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Therapies for immunological and neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Plasma-derived therapies are developed to treat multiple diseases.
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
Detailed competitors of ADMA Biologics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Adma Biologics
Complete news archive for ADMA Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ADMA Biologics
ADMA Biologics was founded in 2005 and raised its 1st funding round 7 years after it was founded.
ADMA Biologics is headquartered in Ramsey, United States. It is registered at Ramsey, Minnesota, United States.
Adam Grossman is the current CEO of ADMA Biologics. They have also founded this company.
ADMA Biologics is a funded company, having raised a total of $17.55M across 6 funding rounds to date.
As of Dec 31, 2024, the latest employee count at ADMA Biologics is 685.
Annual revenue of ADMA Biologics is $426.45M as on Dec 31, 2024.
ADMA Biologics was founded in 2005 and is headquartered in Ramsey, United States. Operations focus on the development, manufacturing, and marketing of plasma-derived immune globulins targeted at niche patient populations. These biologics address primary immune deficiency diseases and certain infectious conditions. The lead product, RI-002, completed phase 3 clinical trials, with a biologics license application submitted to the FDA in 2015.
ADMA Biologics's top competitors include BioNTech, Generate Biomedicines and Kymeratx.
ADMA Biologics offers ASCENIV, BIVIGAM, and Nabi-HB.
Yes, ADMA Biologics is publicly traded on NASDAQ under the ticker symbol ADMA.
ADMA Biologics has 5 investors. Key investors include Hercules Capital, Oxford Finance, Perceptive Advisors, Burrill and Company, and Aisling Capital.
The ticker symbol of ADMA Biologics is ADMA on NASDAQ.